Loading...

SOLARA Solara Active Pharma Sciences Ltd Earnings Reports Announcement

Slr

SLR

Solara Active Pharma Sciences Ltd

(SOLARA)

2026 Announcement

Earnings Call Transcript

Newspaper publication

Rights Offering

Policy Adoption

Rights Issue Proceeds

Auditors Reappointment

Rights conversion

Q4 FY26 Earnings

Audited Financial Results

Audited Annual Results

Conference Call Update

Analyst / Investor Call

Board Meeting for Results

U.S. FDA inspection closure

Regulatory Compliance

Rights Offering

Rights Offering

Trading Window Closure

Second & Final Call

Share transfer window

Rights issue call

Rights Offering and final call

Second & Final Call

Rights Offering

Regulatory Compliance

Rights Offering Conversion

Deregistration of subsidiary

Earnings Conference Call

Newspaper Advertisement

Earnings call recording

Utilization of proceeds

Rights Offering - Second Call

Rights Issue fund utilization

Policy Revisions

Ibuprofen Strategic Options

Unaudited Financial Results

Unaudited Standalone and Co...

Postal Ballot notice / News...

Rights Offering

Analyst Conference Call

Board Meeting Intimation

Regulatory Compliance

Trading Window Closure

Management Committee Recons...

Appointment of Executive Di...

Resignation of Director

Volume Movement Clarification

US FDA inspection closure

Earnings Call Transcript

Financial Results Released

Monitoring Agency Report

Q2 FY26 Earnings Call

Management Changes

No Deviation Reported

New CHRO Appointment

Q2 FY26 Results

Director Resignation

Financial Results Release

Investor Call Announced

ESG Rating Update

Compliance Certificate

Share Allotment

Investor Campaign Announcement

Volume Movement Clarification

AGM Notice Published

Annual General Meeting

100 Days Campaign

Call Money Received

Monitoring Agency Report

Earnings Call Transcript

Financial Results Published

Investor Meet Recording

Q1 2026 Results

Funds Utilization Update

Investor Call Scheduled

SEBI Compliance Certificate

Fractional Shares Reminder

First Call Money Reminder

First Call Reminder

Credit Rating Update

Share Transfer Notice

Annual Compliance Report

Earnings Call Transcript

Financial Results Published

Quarterly Earnings Call

Appointment of Auditors

Management Appointment

Management Retirement

Management Change

No Deviation Reported

Q4 FY25 Results

FDA Inspection Passed

Investor Conference Call

Monitoring Agency Report

Office Address Change

Office Address Change

New Subsidiary Incorporated

Compliance Certificate

Newspaper Publication

First Call Money Notice

Rights Issue Update

Rights Issue Call

Postal Ballot Notice

Subsidiary Closure

Management Resignation

Management Changes

Management Change

Monitoring Agency Report

New Subsidiary Approval

Earnings Call Transcript

Financial Results Published

Earnings Call Audio

Q3 FY25 Results

No Deviations Reported

Board Meeting Update

Investor Call Scheduled

Compliance Certificate

Monitoring Agency Report

Earnings Call Transcript

Financial Results

Funds Utilization Report

Earnings Call Update

Compliance Certificate

Conference Call Scheduled

Annual General Meeting

AGM Announcement

Completion of EU-GMP Inspec...

Resignation of Director

Monitoring Agency Report

Financial Results Publication

Earnings Call Outcome

Deviation Statement

ESOP Plan Introduction

Certificate Submission

Conference Call

Newspaper Advertisement

Allotment Details

Rights Issue Closure

Financial Results Announcement

Compliance Report Submission

Advertisement Publication

Conference Call

FDA Inspection Success

Rights Issue Terms Finalized

Certificate Submission

Update on Shareholding Tran...

Price Movement Clarification

Compliance Certificate Subm...

Certification Submission

Divestment Update

Appointment Of CFO

Management Change

Advertisement - Unaudited F...

Audio recordings of Q3 FY24...

Management Changes

Resignation and Appointment

Conference Call

Certificate Submission

Postal Ballot Notice

Management Change

Change in Designation

Online Dispute Resolution M...

Earnings Call Transcript

Financial Results - Newspap...

Land & Building Sale

Appointment of Directors

Conference Call

Fire Incident Update

CFO Appointment

Certificate under Reg. 74 (...

Financial Statements

Financial Statements

Analyst Questions

Committee Reconstitution

Conference Call

Financial Statements

Completion of Inspection

Conference Call

Appointments, Resignations

Investor Meetings

Appointments, Resignations

Equity Offerings

Management Changes

Equity Offerings

Annual compliance report

Earnings Call Transcript

Financial Statements Public...

Conference Call

External Links:

Data:

Solara reports a strong Q4’26 with 24% QoQ and 36% YoY revenue growth, 53% QoQ EBITDA rise, and margin resilience in the Base business, offsetting Ibuprofen headwinds; highest quarterly metrics in eight quarters.

AI Assistant

Solara Active Pharma Sciences Ltd

2026

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.